Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Leukemia
Reports by J.E. Karp and co-researchers describe recent advances in acute leukemia
March 25th, 2008
According to recent research published in the journal Leukemia Research, "Triapine((R)) is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in adults with refractory acute leukemias and aggressive myeloproliferative disorders (MPD)." "Two schedules were examined: (A) Triapine 105 mg/m(2)/day over 24 h followed by fludarabine daily x 5 (24 patients, fludarabine 15-30 mg/m(2)/dose); (B) Triapine 200mg/m(2) over 24 h followed by 5 days of fludarabine 30 mg/m(2) /day (9 patients). Complete and partial responses...
Source: Cancer Weekly (2008-03-25)
|
